A recent publication in the International Journal of Cardiology, "Pulmonary artery denervation in pulmonary hypertension: A ...

Pulmonary arterial hypertension (PAH) is a rare form of pulmonary hypertension. It occurs because progressive vascular ...

The new drug sotatercept stops the remodelling of the pulmonary vessels and even helps patients with advanced pulmonary arterial hypertension (PAH) who have not yet been treated.

New podcasts from advocacy organization Phaware will highlight treatment advances in pulmonary hypertension tied to ...

Results from the Phase III ZENITH trial show that Winrevair lowered the risk of all-cause death, lung transplantation, and ...

CHICAGO -- Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk ...

Merck, known as MSD outside of the United States and Canada, today announced the first presentation of results from the Phase ...

I took the diet drug Redux in the late 1990s. It was pulled off the market due to correlated heart issues. I saw a cardiologist and learned that ...

Sotatercept, an activin signaling inhibitor, was associated with improved outcomes in patients with advanced pulmonary ...

In the ZENITH trial, Winrevair was evaluated based on a composite endpoint of all-cause death, lung transplantation or disease-related hospitalization for patients with pulmonary arterial hypertension ...

Patients taking sotatercept had a 76% relative risk reduction in morbidity and mortality events compared with patients taking ...

Researchers use machine learning models to investigate patterns between multimorbidity and premature deaths among decedents ...